Related Experiment Videos
Oxygen therapeutics in trauma and surgery
1Daughtry Family Department of Surgery, University of Miami School of Medicine, Ryder Trauma Center, Florida 33101, USA. stephen.cohn@miami.edu
The Journal of Trauma
|May 28, 2003
Summary
New oxygen therapeutics, nearing efficacy trials, offer advantages over red blood cells like longer shelf life and reduced contamination risks. These blood substitutes may soon offer a safe alternative for patient resuscitation.
Area of Science:
- Biomedical Engineering
- Hematology
- Critical Care Medicine
Background:
- Oxygen therapeutics are advancing through Phase III clinical trials.
- Packed red blood cells (PRBCs) are the current standard for oxygen delivery.
- Limitations of PRBCs include short shelf life, viral contamination risks, and immunosuppressive effects.
Purpose of the Study:
- To evaluate the potential advantages and limitations of novel oxygen therapeutics compared to PRBCs.
- To assess the readiness of oxygen therapeutics for clinical application in patient resuscitation.
Main Methods:
- Review of safety trial data and ongoing multicenter Phase III efficacy trials.
- Comparative analysis of oxygen therapeutics' properties versus PRBCs.
- Assessment of clinical applicability based on pharmacokinetic and pharmacodynamic profiles.
Main Results:
- Oxygen therapeutics demonstrate advantages: long shelf life, no cross-matching, reduced contamination, lower viscosity, and potentially fewer immunosuppressive effects.
- These products may offer superior oxygen delivery per unit mass compared to PRBCs.
- A key limitation is their short biologic half-life, restricting use to acute anemia or emergent situations.
Conclusions:
- Safe and effective oxygen therapeutics comparable to PRBCs may soon be available.
- These novel therapies hold significant potential for improving trauma patient resuscitation.
- Further research is needed to optimize half-life and expand clinical applications.